Autologous Stem Cell Transplantation for Multiple Myeloma: Identification of Prognostic Factors

Micro-Abstract Currently, high dose chemotherapy supported by autologous stem cell transplantation (ASCT) is considered a standard treatment approach for multiple myeloma (MM) patients aged 65 years or younger. To evaluate the predictors of outcome after ASCT, we analyzed results of 170 patients. Pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2013-02, Vol.13 (1), p.32-41
Hauptverfasser:	Kumar, Lalit, Cyriac, Sunu L, Tejomurtula, Tilak V.S.V.G.K, Bahl, Ankur, Biswas, Bivas, Sahoo, Ranjit K, Mukherjee, Anjali, Sharma, Omdutt
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents, Alkylating - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemosensitive disease Complete response Disease-Free Survival Female Follow-Up Studies Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation - methods Humans Male Melphalan - therapeutic use Middle Aged Multiple Myeloma - drug therapy Multiple Myeloma - surgery Novel Agents Prognosis Remission Induction Serum M protein Transplant outcome Transplantation Conditioning - methods Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Currently, high dose chemotherapy supported by autologous stem cell transplantation (ASCT) is considered a standard treatment approach for multiple myeloma (MM) patients aged 65 years or younger. To evaluate the predictors of outcome after ASCT, we analyzed results of 170 patients. Pretransplant chemosensitive disease and achievement of complete response (CR) were associated with improved outcome.
ISSN:	2152-2650 2152-2669
DOI:	10.1016/j.clml.2012.08.007